Do analysts rate PHG or GKOS?

Glaukos has a consensus target price of $146.17, suggesting a potential upside of 41.80%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Glaukos 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79

Which has better earnings and valuation, PHG or GKOS?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $20.17B 1.26 $1.01B $1.17 22.54 Glaukos $507.44M 11.93 -$187.69M -$3.28 N/A

Does the media refer more to PHG or GKOS?

In the previous week, Koninklijke Philips and Koninklijke Philips both had 2 articles in the media. Glaukos' average media sentiment score of 0.69 beat Koninklijke Philips' score of 0.00 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, GKOS or ZBH?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 11.93 -$187.69M -$3.28 N/A Zimmer Biomet $8.23B 1.94 $705.20M $3.85 21.42

Is GKOS or ZBH more profitable?

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Zimmer Biomet 9.05% 13.24% 7.28%

Does the media favor GKOS or ZBH?

In the previous week, Zimmer Biomet had 8 more articles in the media than Glaukos. MarketBeat recorded 10 mentions for Zimmer Biomet and 2 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 0.98 beat Glaukos' score of 0.69 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GKOS or SOLV?

Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 11.93 -$187.69M -$3.28 N/A Solventum $8.33B 1.56 $1.56B $8.16 9.21

Is GKOS or SOLV more profitable?

Solventum has a net margin of 17.33% compared to Glaukos' net margin of -34.34%. Solventum's return on equity of 23.51% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Solventum 17.33% 23.51% 7.63%

Does the media favor GKOS or SOLV?

In the previous week, Solventum had 2 more articles in the media than Glaukos. MarketBeat recorded 4 mentions for Solventum and 2 mentions for Glaukos. Glaukos' average media sentiment score of 0.69 beat Solventum's score of 0.38 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, GKOS or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Glaukos. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 11.93 -$187.69M -$3.28 N/A Smith & Nephew SNATS $6.16B 2.06 $625M N/A N/A

Does the media prefer GKOS or SNN?

In the previous week, Glaukos had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 2 mentions for Glaukos and 1 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 0.69 beat Smith & Nephew SNATS's score of 0.00 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, GKOS or PEN?

Penumbra has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 11.93 -$187.69M -$3.28 N/A Penumbra $1.40B 8.92 $177.69M $4.34 73.38

Is GKOS or PEN more profitable?

Penumbra has a net margin of 11.76% compared to Glaukos' net margin of -34.34%. Penumbra's return on equity of 10.87% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Penumbra 11.76% 10.87% 8.45%

Does the media prefer GKOS or PEN?

In the previous week, Penumbra had 1 more articles in the media than Glaukos. MarketBeat recorded 3 mentions for Penumbra and 2 mentions for Glaukos. Penumbra's average media sentiment score of 1.82 beat Glaukos' score of 0.69 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Glaukos (GKOS) Competitors

$103.08 -3.44 (-3.23%)

Closing price 03:59 PM Eastern

Extended Trading

$103.39 +0.31 (+0.30%)

As of 05:40 PM Eastern

Compare

GKOS vs. PHG, ZBH, SOLV, SNN, and PEN

Should you buy Glaukos stock or one of its competitors? MarketBeat compares Glaukos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Glaukos include Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), and Penumbra (PEN). These companies are all part of the "medical equipment" industry.

How does Glaukos compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Koninklijke Philips has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Glaukos has a consensus target price of $146.17, suggesting a potential upside of 41.80%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Koninklijke Philips has a net margin of 5.49% compared to Glaukos' net margin of -34.34%. Koninklijke Philips' return on equity of 13.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Glaukos	-34.34%	-6.92%	-5.25%

In the previous week, Koninklijke Philips and Koninklijke Philips both had 2 articles in the media. Glaukos' average media sentiment score of 0.69 beat Koninklijke Philips' score of 0.00 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.26	$1.01B	$1.17	22.54
Glaukos	$507.44M	11.93	-$187.69M	-$3.28	N/A

Summary

Glaukos beats Koninklijke Philips on 8 of the 15 factors compared between the two stocks.

How does Glaukos compare to Zimmer Biomet?

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Glaukos has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	11.93	-$187.69M	-$3.28	N/A
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.42

Glaukos currently has a consensus price target of $146.17, suggesting a potential upside of 41.80%. Zimmer Biomet has a consensus price target of $102.70, suggesting a potential upside of 24.55%. Given Glaukos' stronger consensus rating and higher possible upside, equities analysts clearly believe Glaukos is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has a net margin of 9.05% compared to Glaukos' net margin of -34.34%. Zimmer Biomet's return on equity of 13.24% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Zimmer Biomet	9.05%	13.24%	7.28%

In the previous week, Zimmer Biomet had 8 more articles in the media than Glaukos. MarketBeat recorded 10 mentions for Zimmer Biomet and 2 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 0.98 beat Glaukos' score of 0.69 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zimmer Biomet beats Glaukos on 10 of the 17 factors compared between the two stocks.

How does Glaukos compare to Solventum?

Glaukos (NYSE:GKOS) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Glaukos has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Solventum has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

In the previous week, Solventum had 2 more articles in the media than Glaukos. MarketBeat recorded 4 mentions for Solventum and 2 mentions for Glaukos. Glaukos' average media sentiment score of 0.69 beat Solventum's score of 0.38 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum has a net margin of 17.33% compared to Glaukos' net margin of -34.34%. Solventum's return on equity of 23.51% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Solventum	17.33%	23.51%	7.63%

Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	11.93	-$187.69M	-$3.28	N/A
Solventum	$8.33B	1.56	$1.56B	$8.16	9.21

Glaukos presently has a consensus target price of $146.17, suggesting a potential upside of 41.80%. Solventum has a consensus target price of $84.25, suggesting a potential upside of 12.14%. Given Glaukos' stronger consensus rating and higher possible upside, equities research analysts clearly believe Glaukos is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Glaukos and Solventum tied by winning 8 of the 16 factors compared between the two stocks.

How does Glaukos compare to Smith & Nephew SNATS?

Glaukos (NYSE:GKOS) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, Glaukos had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 2 mentions for Glaukos and 1 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 0.69 beat Smith & Nephew SNATS's score of 0.00 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Glaukos presently has a consensus price target of $146.17, suggesting a potential upside of 41.80%. Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential upside of 4.07%. Given Glaukos' stronger consensus rating and higher probable upside, equities research analysts clearly believe Glaukos is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Glaukos has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Smith & Nephew SNATS has higher revenue and earnings than Glaukos.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	11.93	-$187.69M	-$3.28	N/A
Smith & Nephew SNATS	$6.16B	2.06	$625M	N/A	N/A

Smith & Nephew SNATS has a net margin of 0.00% compared to Glaukos' net margin of -34.34%. Smith & Nephew SNATS's return on equity of 0.00% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Smith & Nephew SNATS	N/A	N/A	N/A

Summary

Glaukos beats Smith & Nephew SNATS on 9 of the 15 factors compared between the two stocks.

How does Glaukos compare to Penumbra?

Glaukos (NYSE:GKOS) and Penumbra (NYSE:PEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Penumbra has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	11.93	-$187.69M	-$3.28	N/A
Penumbra	$1.40B	8.92	$177.69M	$4.34	73.38

In the previous week, Penumbra had 1 more articles in the media than Glaukos. MarketBeat recorded 3 mentions for Penumbra and 2 mentions for Glaukos. Penumbra's average media sentiment score of 1.82 beat Glaukos' score of 0.69 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Glaukos has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Penumbra has a net margin of 11.76% compared to Glaukos' net margin of -34.34%. Penumbra's return on equity of 10.87% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Penumbra	11.76%	10.87%	8.45%

99.0% of Glaukos shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 2.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Glaukos presently has a consensus price target of $146.17, suggesting a potential upside of 41.80%. Penumbra has a consensus price target of $361.33, suggesting a potential upside of 13.46%. Given Glaukos' stronger consensus rating and higher probable upside, equities research analysts clearly believe Glaukos is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Summary

Penumbra beats Glaukos on 9 of the 16 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$6.05B	$7.14B	$6.41B	$23.17B
Dividend Yield	N/A	1.32%	2.75%	4.07%
P/E Ratio	-31.43	45.56	21.25	30.87
Price / Sales	11.93	74.26	561.59	24.75
Price / Cash	N/A	24.64	43.49	24.96
Price / Book	9.03	7.30	10.60	4.79
Net Income	-$187.69M	$158.10M	$3.56B	$1.07B
7 Day Performance	-14.77%	10.14%	2.84%	1.16%
1 Month Performance	-11.85%	12.87%	6.16%	2.87%
1 Year Performance	8.65%	4.43%	36.73%	27.33%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	3.2202 of 5 stars	$103.08 -3.2%	$146.17 +41.8%	+11.7%	$6.05B	$507.44M	N/A	1,094	Analyst Forecast High Trading Volume
PHG Koninklijke Philips	2.1353 of 5 stars	$26.96 +0.0%	N/A	+15.4%	$25.95B	$20.17B	23.10	65,340
ZBH Zimmer Biomet	4.7156 of 5 stars	$85.41 -0.1%	$102.80 +20.4%	-10.0%	$16.54B	$8.23B	22.19	17,000	Dividend Announcement Analyst Forecast
SOLV Solventum	3.242 of 5 stars	$76.92 +0.1%	$84.25 +9.5%	+4.7%	$13.31B	$8.33B	9.43	20,000
SNN Smith & Nephew SNATS	1.8894 of 5 stars	$30.51 -0.1%	$30.93 +1.4%	+4.0%	$13.04B	$6.16B	N/A	16,988

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors

GKOS vs. PHG, ZBH, SOLV, SNN, and PEN

How does Glaukos compare to Koninklijke Philips?

Summary

How does Glaukos compare to Zimmer Biomet?

Summary

How does Glaukos compare to Solventum?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Summary

How does Glaukos compare to Penumbra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glaukos (GKOS) Competitors

GKOS vs. PHG, ZBH, SOLV, SNN, and PEN

How does Glaukos compare to Koninklijke Philips?

Do insiders and institutionals hold more shares of PHG or GKOS?

Which has more risk and volatility, PHG or GKOS?

Do analysts rate PHG or GKOS?

Is PHG or GKOS more profitable?

Does the media refer more to PHG or GKOS?

Which has better earnings and valuation, PHG or GKOS?

Summary

How does Glaukos compare to Zimmer Biomet?

Do insiders & institutionals hold more shares of GKOS or ZBH?

Which has more volatility & risk, GKOS or ZBH?

Which has better valuation & earnings, GKOS or ZBH?

Do analysts prefer GKOS or ZBH?

Is GKOS or ZBH more profitable?

Does the media favor GKOS or ZBH?

Summary

How does Glaukos compare to Solventum?

Do insiders and institutionals have more ownership in GKOS or SOLV?

Which has more volatility and risk, GKOS or SOLV?

Does the media favor GKOS or SOLV?

Is GKOS or SOLV more profitable?

Which has stronger earnings & valuation, GKOS or SOLV?

Do analysts rate GKOS or SOLV?

Summary

How does Glaukos compare to Smith & Nephew SNATS?

Does the media prefer GKOS or SNN?

Do insiders & institutionals have more ownership in GKOS or SNN?

Do analysts recommend GKOS or SNN?

Which has more volatility and risk, GKOS or SNN?

Which has stronger valuation and earnings, GKOS or SNN?

Is GKOS or SNN more profitable?

Summary

How does Glaukos compare to Penumbra?

Which has better valuation & earnings, GKOS or PEN?

Does the media prefer GKOS or PEN?

Which has more volatility and risk, GKOS or PEN?

Is GKOS or PEN more profitable?

Do institutionals & insiders hold more shares of GKOS or PEN?

Do analysts rate GKOS or PEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools